Table 1.
Cytokeratin 5 (CK5) and estrogen receptor (ER) expression in ovarian malignancies
| Tumor type | number of cases | ER–a | ER+ | CK5–b | CK5+c | CK5+/ER+d |
|---|---|---|---|---|---|---|
| Epithelial | ||||||
| Serous | 38 | 6 (16%) | 32 (84%) | 19 (50%) | 19 (50%) Low: 12 (63%) Med: 5 (26%) High: 2 (11%) |
17 (45%) |
| Mucinous | 20 | 13 (65%) | 7 (35%) | 17 (85%) | 3 (15%) Low: 2 (67%) Med: 1 (33%) High: 0 |
3 (15%) |
| Endometrioid | 25 | 4 (16%) | 21 (84%) | 12 (48%) | 13 (52%) Low: 8 (62%) Med: 5 (38%) High: 0 |
13 (52%) |
| Clear cell | 1 | 1 (100%) | 1 (100%) | |||
| Transitional cell | 1 | 1 (100%) | 1 (100%) | |||
| Squamous | 1 | 1 (100%) | 1 (100%) Low: 0 Med: 0 High: 1 |
|||
| Adenocarcinoma, unspecified | 21 | 9 (43%) | 12 (57%) | 15 (71%) | 6 (29%) Low: 2 (33%) Med: 4 (67%) High: 0 |
5 (24%) |
| Total | 107 | 34 (32%) | 73 (68%) | 65 (61%) | 42 (39%) Low: 24 (57%) Med: 15 (36%) High: 3 (7%) |
38 (36%) |
| Non-epithelial | ||||||
| Granulosa cell | 3 | 1 | 2 | 3 | ||
| Thecoma | 5 | 5 | 5 | |||
| Yolk sac tumor | 2 | 2 | 2 | |||
| Dysgerminoma | 2 | 2 | 2 | |||
| Sarcoma | 1 | 1 | 1 | |||
| Total | 13 | 11 | 2 | 13 |
a
Number of cases determined by IHC using a mAB to ER(alpha), positive scored as >1% immunoreactive cells.
b
Number of cases determined by IHC using a mAB to CK5, positive scored as >1% immunoreactive cells.
c
Low, medium, & high scored as percent immunoreactive cells (1-10%, 10-80%, >80%)
d
Scored as having both CK5+ and ER+ cells within the same tumor, regardless of co-expression in the same cells.